<PAGE>


                        SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549
                                   FORM 10-QSB

 [x] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act
     of 1934.
     For the quarterly period ended March 31, 2003.


 [ ] Transition report under Section 13 or 15(d) of the Securities Exchange
     Act of 1934.

     For the transition period from              to


                         Commission File Number: 0-28666


                         AMERICAN BIO MEDICA CORPORATION
        -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)


                  New York                               14-1702188
       -------------------------------------------------------------------
       (State or other jurisdiction of                (I.R.S. Employer
       incorporation or organization)                 Identification No.)


                   122 Smith Road, Kinderhook, New York 12106
                   -------------------------------------------
                    (Address of principal executive offices)


                                  800-227-1243
                           ---------------------------
                           (Issuer's telephone number)


      Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

      Yes [X]    No [ ]

     State the number of shares outstanding of each of the issuer's classes of
common equity as of the latest practicable date:

     20,609,548 Common Shares as of May 13, 2003


     Transitional Small Business Disclosure Format: Yes [ ] No [X]




<PAGE>

                                     PART I
                              FINANCIAL INFORMATION
                        American Bio Medica Corporation
                                 Balance Sheets
<TABLE>
<CAPTION>
                                                                         March 31,      December 31,
                                                                            2003           2002
                                                                        (Unaudited)
                                                                        ------------   --------------
<S>                                                                         <C>              <C>
                               Assets
                               ------
Current assets:
      Cash and cash equivalents                                        $    309,000    $      231,000
      Accounts receivable, net of allowance of $70,000 at March 31,
       2003 and December 31, 2002                                         1,335,000         1,105,000
      Inventory                                                           2,614,000         2,795,000
      Prepaid and other current assets                                      116,000            60,000
                                                                       ------------    --------------

  Total current assets                                                    4,374,000         4,191,000

Property, plant and equipment, net                                        1,390,000         1,457,000
                                                                       ------------    --------------

Total Assets                                                           $  5,764,000    $    5,648,000
                                                                       ============    ==============

                Liabilities and Stockholders' Equity
                ------------------------------------
Current liabilities:
      Accounts payable                                                 $    867,000    $      908,000
      Accrued liabilities                                                   649,000           513,000
      Current portion of mortgages and notes payable and capital
       lease obligations                                                    217,000           184,000
                                                                       ------------    --------------

 Total current liabilities                                                1,733,000         1,605,000

  Long term portion of mortgages payable                                    668,000           673,000
  Long term portion of unearned grant                                        50,000            50,000
                                                                       ------------    --------------

 Total liabilities                                                        2,451,000         2,328,000
                                                                       ------------    --------------

Stockholders' equity:
    Preferred stock; par value $.01 per share; 5,000,000 shares
     authorized; none issued and outstanding
    Common stock; par value $.01 per share;
     50,000,000 shares authorized; 20,609,548 shares
     issued and outstanding at March 31, 2003 and
     December 31, 2002                                                      206,000           206,000
Additional paid-in capital                                               17,788,000        17,788,000
Accumulated deficit                                                     (14,442,000)      (14,435,000)
Treasury stock                                                             (239,000)         (239,000)
                                                                       ------------    --------------

Total stockholders' equity                                                3,313,000         3,320,000
                                                                       ------------    --------------

Total liabilities and stockholders' equity                             $  5,764,000    $    5,648,000
                                                                       ============    ==============
</TABLE>

                 See accompanying notes to financial statements


<PAGE>
                         American Bio Medica Corporation
                            Statements of Operations
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                               For The Three Months Ended
                                                                         March 31,
                                                              -------------------------------
                                                                   2003              2002
                                                              --------------     ------------
<S>                                                                 <C>                <C>
Net sales                                                     $    2,649,000     $  2,208,000
Cost of goods sold                                                 1,170,000          928,000
                                                              --------------     ------------
Gross profit                                                       1,479,000        1,280,000
                                                              --------------     ------------

Operating expenses:
    Research and development                                         206,000          132,000
    Selling and marketing                                            619,000          560,000
    General and administrative                                       663,000          577,000
                                                              --------------     ------------
                                                                   1,488,000        1,269,000
                                                              --------------     ------------
Operating income/(loss)                                               (9,000)          11,000
                                                              --------------     ------------

Other income (expense):

   Other income                                                       12,000           27,000
   Interest income                                                     7,000           27,000
   Interest expense                                                  (17,000)         (11,000)
                                                              --------------     ------------
                                                                       2,000           43,000
                                                              --------------     ------------
Income (loss) before provision for income taxes                       (7,000)          54,000
Provision for (benefit from) income taxes                                  0                0
                                                              --------------     ------------
Net income/(loss) attributable to common shareholders         $       (7,000)    $     54,000
                                                              ==============     ============

Basic and diluted income/(loss) per common share              $         0.00     $       0.00
                                                              ==============     ============

Weighted average shares outstanding  -
    basic and diluted                                             20,609,548       20,609,548
                                                              ==============     ============
</TABLE>

                 See accompanying notes to financial statements


<PAGE>

                         American Bio Medica Corporation
                            Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                           For The Three Months Ended
                                                                                                   March 31,
                                                                                      -----------------------------------
                                                                                            2003               2002
                                                                                      ------------------  ---------------
<S>                                                                                          <C>                <C>
Cash flows from operating activities:
 Net income/(loss)                                                                    $     (7,000)       $      54,000
  Adjustments to reconcile net loss to net cash provided by (used
    in) operating activities:
     Depreciation                                                                           44,000               53,000
     Non cash compensation expense                                                                                6,000
     Accrued interest, related party                                                                            (13,000)
     Gain on sale of land                                                                  (30,000)
     Changes in:
       Accounts receivable                                                                (231,000)            (494,000)
       Inventory                                                                           180,000              442,000
       Prepaid expenses and other current assets                                           (56,000)              18,000
       Restricted cash                                                                                            1,000
       Accounts payable                                                                    (41,000)            (144,000)
       Accrued liabilities                                                                 136,000              (53,000)
                                                                                      ------------        -------------
         Net cash used in operating activities                                              (4,000)            (130,000)
                                                                                      ------------        -------------

Cash flows from investing activities:
  Purchase of property, plant and equipment                                                (96,000)             (10,000)
  Sale of land                                                                             150,000
                                                                                      ------------        -------------
         Net cash provided by/(used in) investing activities                                54,000              (10,000)
                                                                                      ------------        -------------

Cash flows from financing activities:
  Debt payments                                                                             (5,000)              (5,000)
  Capital lease payments                                                                    (6,000)              (5,000)
  Proceeds from line of credit                                                              40,000
  Line of credit payments                                                                   (1,000)
                                                                                      ------------        -------------
         Net cash provided by/(used in) financing activities                                28,000              (10,000)
                                                                                      ------------        -------------

Net increase (decrease) in cash and cash equivalents                                        78,000             (150,000)
Cash and cash equivalents - beginning of period                                            231,000              288,000
                                                                                      ------------        -------------

Cash and cash equivalents - end of period                                             $    309,000        $     138,000
                                                                                      ============        =============

Supplemental disclosures of cash flow information
   Cash paid during year for:
      Interest                                                                        $     14,000        $      11,000

</TABLE>

                 See accompanying notes to financial statements



<PAGE>


Notes to financial statements (unaudited)

                                 March 31, 2003

Note A - Basis of Reporting

         The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-QSB. Accordingly, they do not
include all of the information and footnotes required by accounting principles
generally accepted in the United States of America for complete financial
statements. In the opinion of management, such statements include all
adjustments (consisting only of normal recurring items), which are considered
necessary for a fair presentation of the financial position of American Bio
Medica Corporation (the "Company" or "ABMC") at March 31, 2003, and the results
of its operations, and cash flows for the three-month period then ended. The
results of operations for the three-month period ended March 31, 2003 are not
necessarily indicative of the operating results for the full year. These
financial statements should be read in conjunction with the Company's audited
financial statements and related disclosures for the year ended December 31,
2002 included in the Company's Form 10-KSB.

         During the year ended December 31, 2002, the Company earned net income
of $719,000 from net sales of $10,312,000, and had net cash outflows from
operating activities of $400,000. During the three months ended March 31, 2003,
the Company sustained a net loss of $7,000 from net sales of $2,649,000, and had
net cash used in operating activities of $4,000. The Company continued to take
steps to improve its financial prospects including increased research and
development expenditures, continued development of new products, continued
evaluation of a potential "CLUB-DRUG" panel that could be a useful tool against
the latest drugs of choice including Rohypnol, Ecstasy, Ketamine, Ritalin, GHB
and Methamphetamine, entering into an agreement with an unrelated party to
develop test components for an HIV test, and other measures to enhance profit
margins.

         The Company's continued existence is dependent upon several factors,
including its ability to raise revenue levels and reduce costs to generate
positive cash flows, and to sell additional shares of the company's common stock
to fund operations, if necessary.

NEW ACCOUNTING STANDARDS

         In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 143, Accounting for
Asset Retirement Obligation. SFAS No. 143 requires entities to record the fair
value of a liability for an asset retirement obligation in the period in which
it is incurred. When the liability is initially recorded, an entity capitalizes
a cost by increasing the carrying amount of the long-lived asset. Over time, the
liability is accreted to its present value each period and the capitalized cost
is depreciated over the useful life of the related asset. Upon settlement of the
liability, an entity either settles the obligation for its recorded amount or
incurs a gain or loss upon settlement. SFAS No. 143 is effective for fiscal
years beginning after June 15, 2002. The adoption of this Statement did not have
a material impact on the Company's financial statements.

         In July 2002, the FASB issued SFAS No. 146, Accounting for Costs
Associated with Exit or Disposal Activities. SFAS No. 146 addresses financial
accounting and reporting for costs associated with exit or disposal activities
and nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, Liability
Recognition for Certain Employee Termination Benefits and Other Costs to Exit an
Activity (including Certain Costs Incurred in a Restructuring). This Statement
is effective for exit and disposal activities initiated after December 31, 2002.
The adoption of this Statement did not have a material impact on the Company's
financial statements.

         In November 2002, FASB issued FASB Interpretation No. 45, Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others, an interpretation of FASB Statement No. 5,
57, and 107 and Rescission of FASB Interpretation No. 34 ("FIN 45"). FIN 45
clarifies the requirements of SFAS No. 5, Accounting for Contingencies, relating
to the guarantor's accounting for, and disclosure of, the issuance of certain
types of guarantees. FIN 45 requires that upon issuance of a guarantee, the

<PAGE>

guarantor must recognize a liability for the fair value of the obligation it
assumes under that guarantee. FIN 45 specifically excludes certain guarantee
contracts from its scope. Additionally, certain guarantees are not subject to
FIN 45's provisions for initial recognition and measurement but are subject to
its disclosure requirements. The initial recognition and measurement provisions
are effective for guarantees issued or modified after December 31, 2002. The
disclosure requirements are effective for our annual financial statements for
the year ended December 31, 2002. The Company has adopted the provisions of this
statement, which did not have a material impact on its financial statements.

             In December 2002, the FASB issued SFAS No. 148, Accounting for
Stock Based Compensation--Transition and Disclosure, an amendment to FASB
Statement No. 123. This Statement amends SFAS No. 123, Accounting for
Stock-Based Compensation, to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, this Statement amends the disclosure
requirements of Statement No. 123 to require prominent disclosures in both
annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effect of the method used on reported
results. Finally, SFAS No. 148 amends APB Opinion No. 28, Interim Financial
Reporting, to require disclosure about those effects in interim financial
reporting. For entities that voluntarily change to the fair value based method
of accounting for stock-based employee compensation, the transition provisions
are effective for fiscal years ending after December 15, 2002. For all other
companies, the disclosure provisions and the amendment to APB No. 28 are
effective for interim periods beginning after December 15, 2002. The following
pro forma information gives effect to fair value of the options on the date of
grant using the Black-Scholes option-pricing model with the following
assumptions: dividend yield of 0%, volatility ranging from 84% to 85% for 2003
and 87% to 90% for 2002, risk free interest rates of ranging from 4.69% to 4.98%
for 2003 and 4.98% - 6.04% for 2002, and an expected life of 10 years for both
2003 and 2002. The pro-forma net loss represents three months amortization of
expense associated with the option grants.

<TABLE>
<CAPTION>
                                             Three months ended      Three months ended
                                                   March 31,              March 31,
                                                     2003                   2002
                                           ------------------------ ---------------------
         <S>                                          <C>                      <C>
     Net Income/(loss):
           As reported                            $   (7,000)            $     54,000
           Pro forma                              $ (189,000)            $   (115,000)

     Basic and fully diluted income/(loss)
     per share
         As reported                                  $  .00                    $ .00
         Pro forma                                    $ (.01)                   $(.01)
</TABLE>

         In January 2003, the FASB issued FASB Interpretation No. 46,
Consolidation of Variable Interest Entities ("FIN 46"). FIN 46 requires a
variable interest entity to be consolidated by a company if that company is
subject to a majority of the risk of loss from the variable interest entity's
activities or entitled to receive a majority of the entity's residual returns or
both. FIN 46 also requires disclosures about variable interest entities that a
company is not required to consolidate but in which it has a significant
variable interest. The consolidation requirements of FIN 46 apply immediately to
variable interest entities created after January 31, 2003. The consolidation
requirements apply to existing entities in the first fiscal year or interim
period beginning after June 15, 2003. Certain of the disclosure requirements
apply in all financial statements issued after January 31, 2003, regardless of
when the variable interest entity was established. The Company does not believe
the adoption of this Statement will have a material impact on its financial
statements.


<PAGE>



Note B - Net Income or Loss Per Common Share

         Basic net income or loss per share is calculated by dividing the net
income or loss by the weighted average number of outstanding common shares
during the period. No effect has been given to potential issuances of common
stock including outstanding options and warrants in the diluted computation as
of March 31, 2003 and 2002 respectively, as their effect would be anti-dilutive.

         Potential common shares outstanding as of March 31, 2003 and 2002:
<TABLE>
<CAPTION>
                                                 March 31, 2003        March 31, 2002
                                                 --------------        --------------
                          <S>                         <C>                   <C>
                       Warrants                    2,651,703             2,651,703
                       Options                     5,670,000             4,983,250
</TABLE>


Note C - Litigation

         The Company has no pending litigation as of the date of this report.

Note D - Sale of Land

         On March 31, 2003 the Company sold approximately 85 acres of land at
its Kinderhook headquarters for $150,000 recognizing a gain of $30,000.

Note E - Reclassifications

         Certain items have been reclassified to conform to the current
presentation.


Item 2. Management's Discussion and Analysis or Plan of Operation

         MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2003 AND 2002

         The following discussion of the Company's financial condition and the
results of operations should be read in conjunction with the Financial
Statements and Notes thereto appearing elsewhere in this document.

          The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements. In order to comply with the terms of the
safe harbor, the Company notes that in addition to the description of historical
facts contained herein, this report contains certain forward-looking statements
that involve risks and uncertainties as detailed herein and from time to time in
the Company's other filings with the Securities and Exchange Commission and
elsewhere. Such statements are based on management's current expectations and
are subject to a number of factors and uncertainties, which could cause actual
results to differ materially from those, described in the forward-looking
statements. These factors include, among others: (a) the Company's fluctuations
in sales and operating results; (b) risks associated with international
operations; (c) regulatory, competitive and contractual risks; (d) product
development risks; and (e) the ability to achieve strategic initiatives,
including but not limited to the ability to achieve sales growth across the
business segments through a combination of enhanced sales force, new products,
and customer service.

Critical accounting policies
----------------------------

         There have been no significant changes to the Company's critical
accounting policies, which are included in the Company's 10KSB filing for the
year ended December 31, 2002, during the three months ended March 31, 2003.


Results of operations for the three months ended March 31, 2003 as compared to
the three months ended March 31, 2002
-------------------------------------
<PAGE>

         Net sales were $2,649,000 for the three months ended March 31, 2003 as
compared to $2,208,000 for the three months ended March 31, 2002, representing
an increase of $441,000 or 20.0%. Direct sales, telemarketing sales and
international sales combined to contribute approximately $2,200,000 or 83.1% of
the net sales for the quarter compared to $1,500,000 or 60.3% in the first
quarter of 2002. During the three months ended March 31, 2003, the Company
continued its extensive program to market and distribute its primary product
lines, the Rapid Drug Screen(R) and Rapid One(R), in addition to its saliva
based test, the Oralstat(R) and its recently developed Rapid Tec(R) series.

         The Company continued its program of rebuilding relationships with key
distributors, and executed agreements with several new distributors, expanded
its marketing, and began development of diagnostic tests or test components
using immunoassay lateral flow technology to diversify its product line into the
areas of veterinary medicine, mycotoxin detection, and tuberculosis. In
addition, components for an HIV test are being developed for an unrelated party
and new drugs of abuse tests are being explored. Management believes that sales
from its urine based drug test kits and the OralStat saliva based test will
continue to grow as a result of this focus on the core business and new sales
will increase from new product development.

        Cost of goods sold for the three months ended March 31, 2003 was
$1,170,000 or 44.2% of net sales as compared to $928,000 or 42.0% of net sales
for the three months ended March 31, 2002 reflective of a more costly mix of
products sold. The increase in cost of goods sold is commensurate with the
increase in sales. Gross margins decreased from 58% to 55% primarily due to
price adjustments to secure several large volume contracts for state and
national government accounts as well as several large corporate accounts. The
cost of labor and materials has remained relatively consistent and the Company
continued its efforts to control the costs to produce their product.

         Operating expenses increased 17.3% to $1,488,000 in first three months
of 2003 as compared to $1,269,000 in the same period in 2002. This increase is
attributable to increased investment in research and development with the
addition of a scientist and two technicians, investment in marketing with the
hiring of a director of marketing and a part time assistant, and net increases
in general and administrative expenses

     Management believes that the amount of selling, general and administrative
costs may increase as the Company creates the necessary infrastructure to:
achieve its worldwide drug test marketing and sales goals, continue its
penetration of the direct sales market, reinforce its distributor based sales,
and leverage new product initiatives. However, management has implemented
programs to control the rate of increase of these costs to be more consistent
with the expected sales growth rate of the Company.

Research and development
------------------------

        Research and development ("R&D") expenses for the three months ended
March 31, 2003 were $206,000 or 7.8% of net sales compared to $132,000 or 6.0%
of net sales for the three months ended March 31, 2002. The increase in expense
is primarily due to several new positions added to the R&D group during 2002 and
the first quarter of 2003. A research scientist, along with two laboratory
technicians were added in late 2002 and the first quarter of 2003. These
resources were added as part of management's initiatives to: focus on new
product development to meet the changing needs of the on-site drug of abuse
testing market, continue evaluation of a potential "CLUB-DRUG" panel that could
be a useful tool against the latest drugs of choice including Rohypnol, Ecstasy,
Ketamine, Ritalin, GHB and Methamphetamine, develop test components for an HIV
test currently under development by an unrelated party, and develop new uses of
immunoassay lateral flow technology, specifically in the areas of veterinary
medicine and mycotoxin detection. Management expects increases in R&D expenses
as it explores new markets and uses for its immunoassay technology.

Selling and marketing expense
------------------------------

        Selling and marketing expense was $619,000 in the first quarter of 2003,
an increase of $59,000, from $560,000 in the three months in 2002. This increase
is primarily due to the hiring of a director of marketing and marketing
assistant in early 2003. This increased investment in marketing has been made to
support the Company's other efforts in penetrating direct sales and reinforcing
distributor sales. Increased spending in advertisement, promotion, sales
literature and trade show attendance has been offset by savings in sales expense
resulting from changes to the sales commissions plan in late 2002 and early
2003.

<PAGE>


General and administrative expense
----------------------------------

        General and administrative expense was $86,000 higher in the first
quarter of 2003 than the same period in 2002. Total G&A expense in the first
quarter of 2003 was $663,000 compared to $577,000 in the first three months of
2002. Contributing to this were increases in accounting fees, personnel expense
and insurance costs offset by savings in legal fees and postage.

LIQUIDITY AND CAPITAL RESOURCES AS OF MARCH 31, 2003

        The Company's cash requirements depend on numerous factors, including
product development activities, ability to penetrate the direct sales market,
market acceptance of its new products, and effective management of inventory
levels in response to sales forecasts. The Company expects to devote substantial
capital resources to continue its product development, expand manufacturing
capacity and continue research and development activities. The Company will
examine other growth opportunities including strategic alliances and expects
such activities will be funded from existing cash and cash equivalents, issuance
of additional equity or debt securities or additional borrowings subject to
market and other conditions. The Company believes that its current cash
balances, and cash generated from future operations will be sufficient to fund
operations for the next twelve months. If cash generated from operations is
insufficient to satisfy the Company's working capital and capital expenditure
requirements, the Company may be required to sell additional equity or obtain
additional credit facilities. There is no assurance that such financing will be
available or that the Company will be able to complete financing on satisfactory
terms, if at all.

         The Company has working capital of $2,641,000 at March 31, 2003 as
compared to working capital of $2,586,000 at December 31, 2002. The Company has
historically satisfied its net working capital requirements through cash
generated by proceeds from private placements of equity securities with
institutional investors. The Company has never paid any dividends on its common
shares and anticipates that all future earnings, if any, will be retained for
use in the Company's business and it does not anticipate paying any cash
dividends.

         Net cash used in operating activities was $4,000 for the three months
ended March 31, 2003 compared to $130,000 for the three months ended March 31,
2002. The net cash used in operating activities for the three months ended March
31, 2003 was primarily due to and increase in accounts receivable of $231,000,
resulting from increased sales, an increase in prepaid expenses of $56,000,
primarily due to increased insurance costs, and a decrease in accounts payable
of $41,000, partially offset by an a decrease in inventory of $180,000,
resulting from increased sales and continued efforts to control inventory levels
and an increase in accrued expenses of $136,000 resulting from increases in
personnel costs and the timing of the quarter end in relation to scheduled
payrolls. The net cash used in operating activities for the three months ended
March 31, 2002 was primarily due to an increase in accounts receivable of
$494,000, a decrease in accounts payable of $144,000, and a decrease of accrued
expenses of $53,000, partially offset by net income of $54,000, and a decrease
in inventory of $442,000.

         Net cash provided by investing activities was $54,000 for the three
months ended March 31, 2003 compared to net cash used in investing activities of
$10,000 for the three months ended March 31, 2002. The net cash provided by
investing activities in the first quarter of 2003 was comprised of proceeds from
the sale of approximately 85 acres of land at the Company's headquarters in
Kinderhook, NY totaling $150,000, offset by $96,000 for the purchase of
property, plant and equipment. The net cash used in investing activities in the
first quarter of 2002 was for the purchase of property, plant and equipment.

         Net cash provided by financing activities was $28,000 for the three
months ended March 31, 2003, consisting of capital lease and debt payments
totaling $11,000 offset by proceeds from the Company's line of credit totaling
$40,000. The net cash used in financing activities for the three months ended
March 31, 2002 was for capital lease and debt payments totaling $10,000.

<PAGE>


         At March 31, 2003 and 2002, the Company had cash and cash equivalents
of $309,000 and $138,000, respectively.

         The Company's primary short-term capital and working capital needs
relate to continued support of its research and development programs, opening
new distribution opportunities, focusing sales efforts on segments of the drugs
of abuse testing market that will yield high volume sales, increasing its
manufacturing and production capabilities, and establishing adequate inventory
levels to support expected sales.


DISCLOSURE CONTROLS AND PROCEDURES


         On April 29, 2003, the Company's CEO and CFO reviewed the Company's
disclosure controls and procedures. Based on this evaluation, the Company,
including the CEO and CFO, have concluded that the Company's disclosure controls
and procedures are adequate to ensure the clarity and material completeness of
the Company's disclosure in its periodic reports required to be filed with the
SEC. Additionally, based upon this most recent evaluation, we have concluded
that there were no significant changes in internal controls or other factors
that could significantly affect the internal controls of the company subsequent
to the date of evaluation.


<PAGE>
                                     PART II
                                OTHER INFORMATION


Item 1. Legal Proceedings:

         None

Item 2. Changes in Securities

         None.

Item 3. Defaults upon Senior Securities

         None.

Item 4. Submission of Matters to a Vote of Security-Holders

         None.

Item 5.  Other Information

         None.

Item 6.  Exhibits and Reports on Form 8-K

      (a)  Exhibits

                99.1    Certification of the Chairman of the Board and Chief
                        Executive Officer pursuant to 18 U.S.C. Section 1350,
                        as adopted pursuant to Section 906 of the
                        Sarbanes-Oxley Act of 2002.

                99.2    Certification of the Chief Financial Officer pursuant
                        to 18 U.S.C. Section 1350, as adopted pursuant to
                        Section 906 of the Sarbanes-Oxley Act of 2002.

      (b) Reports on Form 8-K

                  On February 12, 2003, the Company filed a form 8-K related to
          the appointment of Daniel W. Kollin to the Registrant's Board of
          Directors.



<PAGE>


                                   SIGNATURES


     In accordance with the requirements of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.



                                    AMERICAN BIO MEDICA CORPORATION
                                    (Registrant)

                                    By: Keith E. Palmer
                                    -------------------------------------------
                                    EVP of Finance, Chief Financial Officer and
                                    Treasurer (Principal Accounting Officer and
                                    duly authorized Officer)





Dated: May 13, 2003




<PAGE>


CERTIFICATIONS
--------------


I, Gerald A. Moore, certify that:


1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica
Corporation;


2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;


3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;


4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:


a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;


b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and


c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;


5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):


a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and


b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: May 13, 2003


                                                    Gerald A. Moore
                                                    ---------------------------
                                                    Gerald A. Moore
                                                    Chairman, CEO and President

<PAGE>



CERTIFICATIONS
--------------


I, Keith E. Palmer, certify that:


1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica
Corporation;


2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;


3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;


4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:


a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;


b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and


c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;


5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):


a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and


b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: May 13, 2003


                                                     Keith E. Palmer
                                                     -------------------------
                                                     Keith E. Palmer
                                                     Chief Financial Officer